Fig. 7.

Tau protein determination in AD patients’ brain. a Immunodetection of the presence of W-Tau isoforms using W-Tau antibody in two different frontal lateral cortex brain extracts derived from AD patients’ brains (Braak V and VI, respectively). The immunoprecipitate performed with W-Tau antibody was characterized by Westernblotting. Left panel shows the blot developed using W-Tau antibody; right panel using Tau 7.51 antibody. b Western blot analysis of the levels of W-Tau and total Tau in frontal lateral cortical samples of non-demented (n = 9) and AD patients classified according to their Braak stage (Braak I = 3; Braak II n = 6, Braak III n = 3, Braak IV n = 1, and Braak V n = 10, Braak VI n = 8). c Quantification of W-Tau and total Tau protein levels as well as W-Tau/total Tau ratio of each group. One-way ANOVA and Dunnett’s multiple comparisons test were performed and statistical significance of each group with respect to non-demented control individuals was given (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). A.U. arbitrary units